Redx Pharma plc - Redx & Medicines Discovery Catapult awarded grant
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
("Redx" or "the Company")
Strategic collaboration will enable preclinical assessment and inform clinical development strategy for Redx's Porcupine (RXC006) and ROCK2 inhibitors for fibrotic diseases with high unmet medical need
The collaboration combines Redx's expertise in the development of novel small molecule precision medicines, including the Company's Porcupine (RXC006) and Rho-associated protein kinase 2 (ROCK2) inhibitors, together with MDC's expertise in biomarker strategies. The collaboration is expected to enable the progression of anti-fibrotic therapies in an area of high unmet medical need worldwide.
Development of new therapies for the treatment of fibrotic diseases is hampered by the lack of translation between animal models and human disease. In addition, robust biomarker strategies that can be used to stratify patients, predict treatment efficacy and show a meaningful anti-fibrotic response early in clinical development do not exist at present. Therefore, new biomarkers validated and developed through the project are expected to greatly assist the development of new therapies for IPF and improve the likelihood of clinical success.
The project, funded by Innovate
"We are excited to enter into this unique collaboration with Medicines Discovery Catapult and would like to thank Innovate
"This partnership with Redx will allow the development of a robust portfolio of biomarkers for IPF and the progression of anti-fibrotic therapies in a faster and better-informed way. This exciting collaboration will enable us to better address an important and unmet clinical need."
For further information, please contact:
| || |
T: +44 1625 469 920
| || |
| || |
T: +44 20 7894 7000
| || |
| || |
T: +44 20 3705 9330
T: +44 20 3727 1000
| || |
Redx is a
If you would like to sign up to regular alerts from
About Medicines Discovery Catapult
For more information on MDC, please visit: https://md.catapult.org.uk/
About Redx's RXC006 and ROCK2 (Rho-associated protein kinase 2) inhibitors
RXC006, is a first-in-class oral porcupine inhibitor designed to treat idiopathic pulmonary fibrosis (IPF). Porcupine function is required for the secretion of all Wnt family members. Wnt plays a critical role in multiple pathways driving fibrosis progression. Furthermore, upregulation of the Wnt pathway plus aberrant Wnt signalling has been shown in around 50% of IPF patients and is associated with poor prognosis. Following its nomination as a development candidate late last year, RXC006 has successfully progressed into manufacturing and toxicity studies aimed at taking RXC006 into the clinic in 2021.
ROCK2 is an intracellular kinase with multiple cellular functions. ROCK2 signalling plays a key role in both the inflammatory component and the tissue remodelling that drives disease progression in many fibrotic conditions, including IPF. Targeting ROCK2 in fibrosis is a clinically validated approach with KD025, a ROCK2 inhibitor in clinical development for IPF, chronic Graft vs Host Disease (cGvHD) and systemic sclerosis.
Both porcupine and ROCK2 are promising targets for the treatment of fibrosis and Redx have shown efficacy in preclinical models of IPF.
This information is provided by RNS, the news service of the
Quick facts: Redx Pharma PLC
Market Cap: £99.58 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE